XML 57 R46.htm IDEA: XBRL DOCUMENT v3.25.0.1
Fair Value - Additional Information (Details)
 1 Months Ended 12 Months Ended
Sep. 30, 2024
USD ($)
Jul. 31, 2023
USD ($)
Installment
Apr. 07, 2022
Jan. 01, 2022
USD ($)
Oct. 31, 2024
USD ($)
Jul. 31, 2024
USD ($)
Installment
Apr. 30, 2024
USD ($)
Installment
Apr. 30, 2022
USD ($)
Installment
Jan. 31, 2016
USD ($)
shares
Dec. 31, 2024
USD ($)
Installment
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2018
USD ($)
Installment
shares
Nov. 21, 2022
shares
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Change in fair value of warrant liability                     $ 1,274,000    
2018 Notes | Series G Preferred Stock                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Warrant issued to purchase shares | shares                     613,333    
Contingent Consideration                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Interest expense due to passage of time and fixed payment schedule                   $ 1,100,000 $ 3,900,000    
Warrant Liabilities                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Warrant issued to purchase shares | shares                         5,000,000
Change in fair value of warrant liability                   0 (1,300,000)    
Contingent Value Rights | Series F Preferred Stock                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Change in fair value of warrant liability                   $ 0 $ 0    
Percentage of net proceeds                 15.00%        
Contingent Value Rights | Series F Preferred Stock | Ficlatuzumab                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Contingent value rights interest rate                 0.00375%        
Shares issued | shares                 3,999        
Drug interest rate percentage                 15.00%        
Contingent value rights                 $ 500,000        
Integrated Diagnostics, Inc                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Exit fee payment $ 6,100,000                        
Integrated Diagnostics, Inc | Contingent Consideration                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Business acquisition description                   required additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month      
Business acquisition contingent consideration gross margin target                       $ 2,000,000  
Business acquisition contingent consideration gross margin target period                       7 years  
Integrated Diagnostics, Inc | Contingent Consideration | Third Amendment to APA Agreement                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Contingent consideration number of installments | Installment   3       1 1 5          
Milestone payment   $ 3,000,000       $ 8,400,000 $ 5,000,000 $ 2,000,000          
Percentage of interest on installment payments     10.00%                    
Exit fee payment         $ 6,100,000                
Integrated Diagnostics, Inc | Common Stock | Contingent Consideration                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Business acquisition description                   If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.      
Contingent consideration shares | shares                       2,520,108  
Contingent consideration number of installments | Installment                   6   8  
Contingent consideration arrangements, common shares, redemption amount       $ 4,600,000               $ 37,000,000  
Repayments of debt   9,300,000                      
Business combination contingent consideration final payment   $ 37,000,000                      
Contingent consideration cash payment                       $ 37,000,000  
Investment, Type [Extensible Enumeration]                       Repurchase  
Integrated Diagnostics, Inc | Common Stock | Contingent Consideration | Repurchase                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Contingent consideration number of installments | Installment                       2  
Minimum | Contingent Consideration                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range                   11.00%      
Maximum | Contingent Consideration                          
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                          
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range                   16.00%